Released : May 01, 2020 07:00 RNS Number : 5828L MaxCyte, Inc. 01 May 2020 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
Released : April 30, 2020 17:39 RNS Number : 5668L MaxCyte, Inc. 30 April 2020 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER
Released : April 21, 2020 07:00 RNS Number : 2678K MaxCyte, Inc. 21 April 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Reports Final Results for Year Ended 31 December 2019 Gaithersburg, Maryland - 21 April 2020: MaxCyte (LSE: MXCT), the global clinical-stage cell-based
Released : February 20, 2020 18:18 RNS Number : 6728D MaxCyte, Inc. 20 February 2020 SCHEDULE 6 AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan
Released : January 24, 2020 16:31 RNS Number : 9167A MaxCyte, Inc. 24 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 24 January 2020 : MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences
Released : January 20, 2020 07:00 RNS Number : 2421A MaxCyte, Inc. 20 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Revenue exceeds market expectations · Five new gene-editing cell therapy deals signed in 2019; eight clinical and commercial cell
Released : September 18, 2019 07:00 RNS Number : 6880M MaxCyte, Inc. 18 September 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2019 ¾ Strong commercial execution and financial performance with 21% year-over-year revenue growth ¾ Cell
Released : July 17, 2019 07:00 RNS Number : 7557F MaxCyte, Inc. 17 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Significant CARMA™ programme progress, 80+ partnered programmes licensed and strong financial performance with 21% year over year revenue growth
Released : June 19, 2019 07:00 RNS Number : 7254C MaxCyte, Inc. 19 June 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") 2018 Annual Report Gaithersburg, Maryland - 19 June 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that
Gaithersburg, Maryland – May 29, 2019: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia. In his presentation, Mr.
